Correction: Everolimus (EVE) and exemestane (EXE) in patients with advanced breast cancer aged ≥ 65 years: new lessons for clinical practice from the EVA study - Marina Cazzaniga, Claudio Verusio, Mariangela Ciccarese, Alberto Fumagalli, Donata Sartori, Maria Rosaria Valerio, Mario Airoldi, Gabriella Moretti, Corrado Ficorella, Valentina Arcangeli, Lucrezia Diodati, Alberto Zambelli, Antonio Febbraro, Daniele Generali, Mirco Pistelli - Dissemin

Dissemin is shutting down on January 1st, 2025

Language
Login

Published in

Impact Journals, Oncotarget, 77(9), p. 34639-34640, 2018

DOI: 10.18632/oncotarget.26213

Links

Tools

Export citation

Search in Google Scholar

Correction: Everolimus (EVE) and exemestane (EXE) in patients with advanced breast cancer aged ≥ 65 years: new lessons for clinical practice from the EVA study

Journal article published in 2018 by Marina Cazzaniga, Claudio Verusio, Mariangela Ciccarese, Alberto Fumagalli, Donata Sartori, Maria Rosaria Valerio, Mario Airoldi, Gabriella Moretti, Corrado Ficorella, Valentina Arcangeli, Lucrezia Diodati, Alberto Zambelli, Antonio Febbraro, Daniele Generali, Mirco Pistelli and other authors.

This paper is made freely available by the publisher.

This paper is made freely available by the publisher.

Full text: Download

Red circle

Preprint: archiving forbidden

Red circle

Postprint: archiving forbidden

Green circle

Published version: archiving allowed

Upload

Policy details

Data provided by

SHERPA/RoMEO